Table 2.

Results of univariate and multivariate analysis of progression-free survival

Variable	Univariate*		Multivariate†
	HR	p value	HR	p value
Age (continuous)	1.16 (1.04–1.29)	0.006	1.18 (1.03–1.34)	0.02
Stage	—	< 0.001	—	< 0.001
II v. I	1.58 (0.80–3.14)	0.2	1.39 (0.68–2.88)	0.4
III v. I	4.92 (3.06–7.91)	< 0.001	2.67 (1.50–4.76)	< 0.001
IV v. I	11.40 (6.16–21.01)	< 0.001	3.98 (1.80–8.81)	< 0.001
Residual disease (any v. none visible)	3.88 (2.85–5.28)	< 0.001	2.42 (1.65–3.57)	< 0.001
Platinum-based chemotherapy	—	0.002	—	—
Any v. none	9.87 (2.45–39.77)	0.001	—	—
Unknown v. none	4.75 (1.13–19.96)	0.03	—	—
Race (White v. other)	0.63 (0.37–1.07)	0.09	0.68 (0.38–1.24)	0.2

HR = hazard ratio.

^*Number of complete observations: age 381, stage 367, residual disease 338, platinum-based primary chemotherapy 381, race 296.

^†Number of complete observations: 333.